Brick & Kyle Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Brick & Kyle Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-150	Closed	-$16K	–	352
2017 Q1	$16K	Hold	150	–	–	0.01%	309
2016 Q4	$11K	Hold	150	–	–	0.01%	344
2016 Q3	$13K	Hold	150	–	–	0.01%	324
2016 Q2	$13K	Hold	150	–	–	0.01%	322
2016 Q1	$12K	Hold	150	–	–	0.01%	331
2015 Q4	$19K	Hold	150	–	–	0.02%	265
2015 Q3	$16K	Hold	150	–	–	0.02%	295
2015 Q2	$19K	Hold	150	–	–	0.02%	294
2015 Q1	$18K	Buy	+150	New	+$18K	0.02%	295

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brick & Kyle Associates's VRTX Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 150 shares — an estimated $16K sold.

Brick & Kyle Associates first reported a position in VRTX in Q1 2015 and held it in 9 quarters. The position peaked at $19K in Q4 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Brick & Kyle Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 150 Vertex Pharmaceuticals shares in Q2 2017, an estimated $16K.
Brick & Kyle Associates first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Brick & Kyle Associates's Vertex Pharmaceuticals position peaked at $19K in Q4 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.